Literature DB >> 21242854

Drug-induced graves disease from CTLA-4 receptor suppression.

Gary Borodic1, David M Hinkle, Yihong Cia.   

Abstract

Monoclonal antibody, ipilimumab, useful for treatment of metastatic melanoma, blocks CTLA-4 mediated T-cell suppression and can also cause a Graves ophthalmopathy like syndrome. Epidemiologic study has linked variant polymorphisms of CTLA-4 receptor gene to the presence of thyroid eye disease. The combination of these observations suggests CTLA-4 mediated T-cell functions are important to the pathogenesis of thyroid-associated eye disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21242854     DOI: 10.1097/IOP.0b013e3181ef72a1

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  31 in total

Review 1.  Anticancer Drug-induced Thyroid Dysfunction.

Authors:  Saptarshi Bhattacharya; Alpesh Goyal; Parjeet Kaur; Randeep Singh; Sanjay Kalra
Journal:  Eur Endocrinol       Date:  2020-02-04

Review 2.  Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.

Authors:  Xiang-Yang Wang; Daming Zuo; Devanand Sarkar; Paul B Fisher
Journal:  Expert Opin Pharmacother       Date:  2011-12       Impact factor: 3.889

Review 3.  Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies.

Authors:  David J Byun; Jedd D Wolchok; Lynne M Rosenberg; Monica Girotra
Journal:  Nat Rev Endocrinol       Date:  2017-01-20       Impact factor: 43.330

4.  Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma.

Authors:  Charlée Nardin; Sophie Borot; Marie-Astride Beaudoin; Françoise Cattin; Eve Puzenat; Anne-Sophie Gauthier; Franck Schillo; Christophe Borg; François Aubin
Journal:  Invest New Drugs       Date:  2018-08-25       Impact factor: 3.850

5.  Immune-Related Thyroiditis with Immune Checkpoint Inhibitors.

Authors:  Priyanka C Iyer; Maria E Cabanillas; Steven G Waguespack; Mimi I Hu; Sonali Thosani; Victor R Lavis; Naifa L Busaidy; Sumit K Subudhi; Adi Diab; Ramona Dadu
Journal:  Thyroid       Date:  2018-10       Impact factor: 6.568

Review 6.  Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

Authors:  J Naidoo; D B Page; B T Li; L C Connell; K Schindler; M E Lacouture; M A Postow; J D Wolchok
Journal:  Ann Oncol       Date:  2015-09-14       Impact factor: 32.976

Review 7.  Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events.

Authors:  Elisa González-Rodríguez; Delvys Rodríguez-Abreu
Journal:  Oncologist       Date:  2016-06-15

Review 8.  Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma.

Authors:  Shannon K Quirk; Anna K Shure; Devendra K Agrawal
Journal:  Transl Res       Date:  2015-06-11       Impact factor: 7.012

Review 9.  Time to dissect the autoimmune etiology of cancer antibody immunotherapy.

Authors:  Michael Dougan; Massimo Pietropaolo
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

Review 10.  Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports.

Authors:  Meng H Tan; Ravi Iyengar; Kara Mizokami-Stout; Sarah Yentz; Mark P MacEachern; Li Yan Shen; Bruce Redman; Roma Gianchandani
Journal:  Clin Diabetes Endocrinol       Date:  2019-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.